-— There is no vaccine. -—
Glaxo has one in Phase 2 trials in West Africa. 10,000 doses are projected to be ready in 6 months.
In Mali, GlaxoSmithKline has teamed up with the Center for Vaccine Development of Mali and the Ministry of Health of Mali to administer its cAd3-ZEBOV vaccine to a total of 40 healthcare workers. Glaxo has been working with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases on its jab, which uses a chimpanzee cold virus vector containing two ebolavirus gene segments that switch on a protein to activate an immune response in the body. A parallel trial in Gambia is expected to begin soon.